"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation"

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to see if campath-1H can be used in first time renal transplant subjects to prevent rejection and reduce the overall amount of anti-rejection medications that patients take on a daily basis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Wisconsin, Madison
• Treatments: Alemtuzumab

Criteria

Inclusion Criteria:

• primary renal transplant (not HLA identical)

• ages 18-60 years

Exclusion Criteria:

• recipient panel reactive antibody level >10%

• recipient of a DCD kidney

• no prior organ transplant

• no multi-organ transplant recipient

• no subject who is currently receiving systemic corticosteroids

• no pregnant or lactating subjects

• no history of Hepatitis B, C or HIV positivity

• no recipient of a kidney with cold ischemia time >36 hours